Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Int J Cancer. 2011 Nov 9;131(3):E292–E303. doi: 10.1002/ijc.26442

Figure 1. Zyflamend inhibits proliferation, induces apoptosis and cell cycle arrest in pancreatic cancer cells in vitro.

Figure 1

(A) Zyflamend inhibits the proliferation of pancreatic cancer cells. MTT assay results showed dose-dependent suppression of cell proliferation in all four pancreatic cancer cell lines tested. Points, mean of triplicate; bars, SE. (B) Cells (2000 cells/well) were seeded in triplicate onto 96-well plates, treated with the indicated concentration of Zyflamend for 72 h, and then measured cell viability by the MTT method and presented as percent cell viability. Points, mean of triplicate; bars, SE (*P < 0.05, **P < 0.01, ***P < 0.001 vs. untreated cells). (C) MIA PaCa-2 cells were incubated with the indicated concentration of Zyflamend for 24 h and then incubated with anti-annexin V antibody conjugated with fluorescein isothiocyanate and then analyzed with a flow cytometer for early apoptotic effects.